Focus: Lee's Pharmaceutical is a publicly traded Chinese pharmaceutical company headquartered in Guangzhou specializing in small molecule therapeutics across oncology, cardiovascular, neurology, and nephrology indications.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
Lee's offers meaningful exposure to oncology and cardiovascular R&D with an established product base, but severely constrained hiring and early-stage pipeline visibility make it suitable only for candidates prioritizing scientific focus over near-term career acceleration.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Marquee NDA-approved product at peak commercial stage, serving as the primary revenue driver and financial anchor for pipeline investment.
Help build intelligence for Lee's Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lee's Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Recent peer-reviewed publications with author affiliations at this company
Phase I Clinical Study of a Multi-Kinase Inhibitor TG02 Capsule for the Treatment of Recurrent High-Grade Gliomas with Failed Temozolomide Treatment in Chinese Patients.
Efficacy and Safety of a Fixed-Dose Combination Gel with Adapalene 0.1% and Clindamycin 1% for the Treatment of Acne Vulgaris (CACTUS): A Randomized, Controlled, Assessor-Blind, Phase III Clinical Trial.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo